Skip to main content
OpenTrials

Clinical trial condition

Neisseria Meningitidis

Explore clinical trials studying Neisseria Meningitidis. Study availability and eligibility vary by location and protocol.

34 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Neisseria Meningitidis trial results

Completed

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

NCT00586612

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Barcelona, Spain
  • GSK Investigational Site Bilbao, Spain
  • GSK Investigational Site Burgos, Spain
  • GSK Investigational Site Getafe, Spain
View Trial Details
Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

NCT00326118

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Garran, Australian Capital Territory, Australia
  • GSK Investigational Site Randwick, New South Wales, Australia
  • GSK Investigational Site Westmead, New South Wales, Australia
  • GSK Investigational Site Herston, Queensland, Australia
View Trial Details
Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Centennial, Colorado, United States
  • GSK Investigational Site Norwich, Connecticut, United States
View all 27 locations
View Trial Details
Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bryant, Arkansas, United States
View all 93 locations
View Trial Details
Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

NCT01090453

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +33 more
Locations
  • GSK Investigational Site Vancouver, British Columbia, Canada
  • GSK Investigational Site Winnipeg, Manitoba, Canada
  • GSK Investigational Site Hamilton, Ontario, Canada
  • GSK Investigational Site Aix-en-Provence, France
View all 34 locations
View Trial Details
Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

NCT00871338

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Ely, Cambridgeshire, United Kingdom
  • GSK Investigational Site Southampton, Hampshire, United Kingdom
  • GSK Investigational Site Oxford, Oxfordshire, United Kingdom
  • GSK Investigational Site Bristol, United Kingdom
View Trial Details
Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

NCT00891176

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bretten, Baden-Wurttemberg, Germany
  • GSK Investigational Site Ettenheim, Baden-Wurttemberg, Germany
  • GSK Investigational Site Karlsruhe, Baden-Wurttemberg, Germany
View all 28 locations
View Trial Details

Related conditions